title: Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.
abstract: OBJECTIVE
  The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach.
  
  
  METHODS
  Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews.
  
  
  RESULTS
  Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended.
  
  
  CONCLUSIONS
  The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations.
authors.affiliation: Phoenix Neurological Associates, Phoenix, AZ, USA.
authors.forename: Barry
authors.initials: B
authors.lastname: Hendin
authors.affiliation: Neurology & Neuroscience Associates, Akron, OH, USA.
authors.forename: DeRen
authors.initials: D
authors.lastname: Huang
authors.affiliation: Hope Neurology, Knoxville, TN, USA.
authors.forename: Sibyl
authors.initials: S
authors.lastname: Wray
authors.affiliation: Department of Neurology, Washington University in St Louis, St Louis, MO, USA.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Naismith
authors.affiliation: fit2market, New York, NY, USA.
authors.forename: Sheri
authors.initials: S
authors.lastname: Rosenblatt
authors.affiliation: Biogen, Cambridge, MA, USA.
authors.forename: Javier
authors.initials: J
authors.lastname: Zambrano
authors.affiliation: Biogen, Cambridge, MA, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Werneburg
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D003697:Delphi Technique; D003875:Drug Eruptions / Q000209:etiology* / Q000628:therapy; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D009288:Naproxen / Q000008:administration & dosage / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D011092:Polyethylene Glycols; D009288:Naproxen; D016899:Interferon-beta; C428112:peginterferon beta-1a
keywords: Delphi; adverse event management; peginterferon β-1a